BioSpace News Archive

Year

• 2005
• 2006
• 2007
• 2008
• 2009
• 2010
• 2011
• 2012
• 2013
• 2014
• 2015
• 2016
• 2017
• 2018
• 2019
• 2020
• 2021
• 2022
• 2023
• 2024
• 2025
• 2026

Month

• January
• February
• March
• April
• May
• June
• July
• August
• September
• October
• November
• December

Day

• 1
• 5
• 6
• 7
• 8
• 11
• 12
• 13
• 14
• 15
• 18
• 19
• 20
• 21
• 22
• 25
• 26
• 27
• 28
• 29

• Policy

  LabCorp Objects To Proposed PAMA 2018 Medicare Payment Rates For Clinical Laboratory Tests; Calls For Delay In Implementation To Avoid Significant Harm To Medicare Beneficiaries

  September 25, 2017

   · 

  3 min read
• PROMETHERA Biosciences S.A./N.V. To Present At Several International Partnering And Scientific Conferences This Fall

  September 25, 2017

   · 

  1 min read
• Drug Development

  Exelixis Provides Update On Collaborator Daiichi Sankyo, Inc.’s Phase III Clinical Progress With Esaxerenone (CS-3150), Including Positive Top-Line Results And Additional Pivotal Study

  September 25, 2017

   · 

  11 min read
• Drug Development

  NovoCure Release: Combination Of Optune With Temozolomide Demonstrates Unprecedented Five-Year Survival For Newly Diagnosed Glioblastoma Patients

  September 25, 2017

   · 

  9 min read
• FDA

  Bristol-Myers Squibb’s Opdivo (Nivolumab) Receives FDA Approval For The Treatment Of Hepatocellular Carcinoma Patients Previously Treated With Sorafenib

  September 25, 2017

   · 

  18 min read
• FDA

  Agilent Receives Expanded FDA Approval For The Use Of Dako PD-L1 IHC 22C3 Pharmdx Companion Diagnostic In Gastric Or Gastroesophageal Junction (GEJ) Cancer

  September 25, 2017

   · 

  4 min read
• Business

  NantKwest Builds Financial And Commercial Expertise With The Appointment Of Fred Driscoll To Its Board Of Directors

  September 25, 2017

   · 

  4 min read
• Deals

  Celcuity Announces Closing Of Initial Public Offering

  September 25, 2017

   · 

  2 min read
• Business

  Enzo Biochem Schedules Teleconference To Discuss Fourth Quarter 2017 Results Thursday September 28, 2017 At 8:30 AM E.T.

  September 25, 2017

   · 

  2 min read
• FDA

  FDA Approves Merck & Co.’s KEYTRUDA (Pembrolizumab) For Previously Treated Patients With Recurrent Locally Advanced Or Metastatic Gastric Or Gastroesophageal Junction Cancer Whose Tumors Express PD-L1 (CPS Greater Than Or Equal To 1)

  September 25, 2017

   · 

  1 min read